Compare Mesoblast Limited (MESO) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Total World Stock Index Fund ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Vanguard Total World Stock Index Fund ETF trades at $159.69 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 56.2× Mesoblast Limited's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| MESO | VT | |
|---|---|---|
Market Cap | $1.81B | $101.70B |
Volume | 240,620 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $20.96 | $162.39 |
52-Week Low | $13.19 | $134.19 |
Typical Hold Time | 14 Days | 53 Days |
Enterprise Value | $1.89B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Vanguard Total World Stock ETF (VT) trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains strong global diversification with over 9,700 holdings across developed and emerging markets. Recent news highlights VT's competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF, with analysts noting its comprehensive exposure and long-term performance advantages.
VT offers investors broad global equity exposure with low costs, though its expense ratio of 0.06% faces pressure from cheaper alternatives. The ETF's performance remains tied to global economic conditions, with risks including trade policy uncertainty and currency fluctuations. Analyst sentiment is generally positive for long-term diversification strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
